Long-term therapy with NTBC and tyrosine-restricted diet in a murine model of hereditary tyrosinemia type I

Molecular Genetics and Metabolism

Volumn 75, Issue 1, 2002, Pages 38-45

  Al Dhalimy, M ^a   Overturf, K ^a   Finegold, M ^b   Grompe, M ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

Hepatocarcinoma; Hereditary tyrosinemia; Liver disease; Treatment; Tyrosine

Indexed keywords

2 (2 NITRO 4 TRIFLUOROMETHYLBENZOYL) 1,3 CYCLOHEXANE DIONE; CYCLOHEXANE DERIVATIVE; SUCCINYLACETONE; TYROSINE; UNCLASSIFIED DRUG;

AGE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; CANCER INCIDENCE; CONTROLLED STUDY; DIET RESTRICTION; DISEASE MODEL; FOLLOW UP; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; LONG TERM CARE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; TREATMENT OUTCOME; TYROSINEMIA;

ANIMALIA; MURINAE;

EID: 0036352728     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1006/mgme.2001.3266     Document Type: Article

References (26)

1. On the enzymic defects in hereditary tyrosinemia
2. Hypertyrosinemia
3. Hereditary tyrosinemia type I - An overview
4. Visceral pathology of hereditary tyrosinemia type I
5. Dietary management of hereditary tyrosinemia. Apropos of 7 cases
6. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinemia type I
7. Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia
8. Liver transplantation in type I tyrosinemia
9. Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh
10. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase
11. Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione)
12. Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice
13. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I
14. Therapeutic trials in the murine model of hereditary tyrosinemia type I: A progress report
15. Comparative utilization of a crystalline amino acid diet and a methionine fortified casein diet by young rats and mice
16. Succinylacetone
17. Nontransplant treatment of tyrosinemia
18. Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice
19. In vivo suppressor mutations correct a murine model of hereditary tyrosinemia type I
20. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway
21. Tissue distribution of 2-(2-nitro-4-trifluoro-methylbenzoyl)-cyclohexane-1,3-dione (NTBC) and its effect on enzymes involved in tyrosine catabolism in the mouse
22. Consequences of complexity within biological networks: Robustness and health, or vulnerability and disease
23. Modifier genes convert "simple" Mendelian disorders to complex traits
24. Phenotypes of patients with "simple" Mendelian disorders are complex traits: Thresholds, modifiers, and systems dynamics
25. Monogenic traits are not simple: Lessons from phenylketonuria
26. The mutagenicity of the tyrosine metabolite, fumarylacetoacetate, is enhanced by glutathione depletion